Noom Segmented GLP-1 Access Strategy

Noom is turning GLP-1 access into a segmented checkout funnel instead of a single drug offer. Lower priced compounded microdoses let it serve cash pay users who want a cheaper and gentler starting point, while the LillyDirect and Gifthealth integration lets it keep higher acuity or brand seeking patients inside the same app with prescription status and shipping updates, even as FDA pressure makes compounding narrower over time.

• The key split is not just price, it is regulation. FDA said on February 21, 2025 that semaglutide shortage conditions were resolved and set end dates for enforcement discretion, which makes manufacturer linked access more valuable as a durable channel while compounded access becomes harder to rely on.
  3 fda
• This also mirrors where the category is going. Ro and Hims moved from compounded GLP-1s toward LillyDirect and NovoCare partnerships after shortages eased, because telehealth platforms need legal branded supply once compounding stops being the default workaround for coverage denied patients.
  5 sacra
• Noom has an advantage that pure prescription funnels do not. Its core product already bundles food logging, activity tracking, chatbot and coach support, so it can monetize both the medication transaction and the longer habit change workflow that helps patients stay on drug and adjust dose over time.
  2 sacra 4 noom

The next step is a market where drug access gets cheaper and more standardized, and the winner captures the patient relationship around it. Noom is positioning to be the weight loss front end that can route each member to the right medication path, then keep earning through adherence, coaching, and program layering after the prescription is filled.